5.69 USD
▲+0.09+3.08%
盘后 5.52 0.00%
2026-08-03
市值
$540.54M
市盈率
—
EPS
-1.07
股息率
—
52 周区间
1.39 – 7.44
成交量
702.66K
Beta
-0.04
目标价
15.67
52W 低 1.3952W 高 7.44
价格走势
公司简介
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and C...